Natural D240G Toho-1 mutant conferring resistance to ceftazidime: Biochemical characterization of CTX-M-43

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 991-997

  Celenza, Giuseppe ^a   Luzi, Carla ^a   Aschi, Massimiliano ^a   Segatore, Bernardetta ^a   Setacci, Domenico ^a   Pellegrini, Cristina ^a   Forcella, Chiara ^a   Amicosante, Gianfranco ^a   Perilli, Mariagrazia ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Acinetobacter baumannii; Antibiotic resistance; Class A; CTX M type enzymes

Indexed keywords

AMINO ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ASPARAGINE; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARUMONAM; CEFALORIDINE; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTIBUTEN; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; ERTAPENEM; GLYCINE; IMIPENEM; LATAMOXEF; MEROPENEM; MUTANT PROTEIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; TAZOBACTAM; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ACYLATION AND DEACYLATION; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; BOLIVIA; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME KINETICS; ESCHERICHIA COLI; INOCULATION; MICHAELIS CONSTANT; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; STEADY STATE; STRUCTURE ANALYSIS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; BOLIVIA; CEFTAZIDIME; ESCHERICHIA COLI; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTATION, MISSENSE; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 54549096036     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn339     Document Type: Article

References (30)

1. Bradford PA. Extended-spectrum β-Lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
2. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
3. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-86.
4. Stürenburg E, Mack D. Extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory, therapy and infection control. J Infect 2003; 47: 273-95.
5. Bonnet R. Growing group of extended-spectrum β-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
6. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: Changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
7. Ishii Y, Ohno A, Taguchi H et al. Cloning and sequence of the gene encoding a celotaxime-hydrolyzing class A β-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother 1995; 39: 2269-75.
8. Ibuka AS, Ishii Y, Galleni M et al. Crystal structure of extended-spectrum β-lactamase Toho-1: Insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Biochemistry 2003; 42: 10634-43.
9. Shimamura T, Ibuka A, Fushinobu S et al. Acyl-intermediate structures of the extended-spectrum class A β-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin. J Biol Chem 2002; 277: 46601-8.
10. Bae IK, Lee BH, Hwang HY et al. A novel ceftazidime-hydrolysing extended-spectrum β-lactamase, CTX-M-54, with a single amino acid substitution at position 167 in the omega loop. J Antimicrob Chemother 2006; 58: 315-9.
11. Chen Y, Delmas J, Sirot J et al. Atomic resolution structures of CTX-M β-lactamases: Extended spectrum activities from increased mobility and decreased stability. J Mol Biol 2005; 348: 349-62.
12. Poirel L, Gniadkowski M, Nordmann P et al. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J Antimicrob Chemother 2002; 50: 1031-4.
13. Bonnet R, Dutour C, Sampaio JLM et al. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240→Gly. Antimicrob Agents Chemother 2001; 45: 2269-75.
14. Bonnet R, Recule C, Baraduc R et al. Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother 2003; 52: 29-35.
15. Cartelle M, del Mar Tomas M, Molina F et al. High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly subsbtution. Antimicrob Agents Chemother 2004; 48: 2308-13.
16. PER-2 β-lactamase genes in clinical isolates from Bolivian hospitals. J Antimicrob Chemother 2006; 57: 975-8.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
18. Perilli M, Celenza G, De Santis F et al. E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum β-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. Antimicrob Agents Chemother 2008; 52: 915-9.
19. Perilli M, Ettorre D, Segatore B et al. Overexpression system and biochemical profile of CTX-M-3 extended-spectrum β-lactamase expressed in Escherichia coli. FEMS Microbiol Lett 2004; 241: 229-32.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
21. Laemmli UK. Cleavage of structural proteins during the assembly of bacteriophage T4. Nature 1970; 227: 680-5.
22. Copeland RA. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, 2nd edn. New York: John Wiley & Sons, 2000.
23. Cornish-Bowden A. Fundamentals of Enzyme Kinetics, 1st edn. London: Portland Press Ltd, 1995.
24. Segel IH. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, 1st edn. New York: John Wiley & Sons, 1975.
25. De Meester F, Joris B, Reckinger G et al. Automated analysis of enzyme inactivation phenomena. Application to β-lactamases and DD-peptidases. Biochem Pharmacol 1987; 36: 2393-403.
26. Galleni M, Franceschini N, Quinting B et al. Use of the chromosomal class A β-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory β-lactam compounds. Antimicrob Agents Chemother 1994; 38: 1608-14.
27. Van der Spoel D, van Drunen R, Berendsen HJC. GROMACS. Department of Biophysical Chemistry, BIOSON Research Institute, Groningen, 1994.
28. Van Gusteren WF, Billeter SR, Eising AA et al. Biomolecular Simulation: The GROMOS96 Manual and User Guide. Zurich: Hochschulverlag AG an der ETH, 1996.
29. Delmas J, Chen Y, Prati F et al. Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum β-lactamases. J Mol Biol 2008; 375: 192-201.
30. Ibuka AS, Matsuzawa H, Sakai H. An engineered disulfide bond between residues 69 and 238 in extended-spectrum β-lactamase Toho-1 reduces its activity toward third-generation cephalosporins. Biochemistry 2004; 43: 15737-45.